| Literature DB >> 33329487 |
Yitao Duan1, Huihui Gao2, Liyang Zheng2, Shuangqing Liu3, Yang Cao3, Siyuan Zhu1, Zhenzhe Wu1, Hongqiang Ren4, Daqing Mao2, Yi Luo1,4.
Abstract
Extraintestinal pathogenic Escherichia coli (ExPEC) can cause many human extraintestinal infections. Resistance and virulence of ExPEC are inextricably linked to its phylogenetic background. However, studies on type-specific distribution of resistance and virulence and the connection between resistance/virulence and molecular typing are lacking. Here, 411 ExPEC strains were collected and characterized using antimicrobial susceptibility testing and molecular typing. Among these, 74 representative strains were selected for whole genome sequencing and the Galleria mellonella killing assay. CH40-30-ST131, CH37-27-ST405, CH40-41-ST131, and CH13-5-ST12 isolates had high resistance rates to all antimicrobials tested. Bla CTX-M played a significant role in the β-lactam resistance of ExPEC isolates. CH14-64-ST1193, CH40-30-ST131, and CH35-27-ST69 isolates were highly virulent in the G. mellonella model. Virulence factors (VFs) involved in adherence (papB, papI, papX, and fimA), autotransporter (sat), invasion (aslA, kpsD), iron uptake (except for entD), or toxin (senB) might be responsible for pathogenicity in vivo. Specific antibiotic resistance genes (ARGs) or VFs were prevalent in specific types of strains, including papB, papI, fimA, sat, kpsD, senB, and aerobactin genes in CH14-64-ST1193 isolates; bla CTX-M- 15, aac(6')-Ib-cr, papB, papI, sat, iucA, iucB, iucC, chuT, chuX, and shuU in CH40-30-ST131 isolates; tetB in CH35-27-ST69 and CH13-5-ST12 isolates. Type distribution also differed by VF score. CH37-27-ST405 and CH26-5-ST38 isolates carried more ARGs and VFs indicating that they had a high resistance and virulence potential. This study demonstrates the type-specific distribution of resistance and virulence thus providing a basis for further research, prevention and treatment of ExPEC infections.Entities:
Keywords: CH typing; extraintestinal pathogenic Escherichia coli; multilocus sequence typing; resistance; virulence
Year: 2020 PMID: 33329487 PMCID: PMC7732638 DOI: 10.3389/fmicb.2020.598305
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Antimicrobial resistance according to CH or ST types among the 411 ExPEC isolates.
| Antimicrobial resistancec | ||||||||||||||
| Amikacin ( | 22 (6.2) | 3 (7) | 3 (9.4) | 0 | 0 | 2 (15.4) | 1 (6.7) | 0 | 2 (22.2) | 1 (8.3) | 1 (11.1) | 0 | 9 (5.4) | 0.370 |
| Gentamicin ( | 168 (56.6) | 15 (53.6) | 25 (75.8) | 8 (61.5) | 5 (41.7) | 11 (68.8) | 10 (83.3) | 3 (37.5) | 7 (77.8) | 8 (72.7) | 5 (71.4) | 0 | 71 (51.4) | 0.001 |
| Amoxillin/clavulanic acid ( | 180 (63.2) | 15 (51.7) | 22 (77.3) | 10 (52.6) | 6 (54.5) | 12 (100) | 10 (90.9) | 5 (71.4) | 5 (71.4) | 8 (66.7) | 4 (66.7) | 8 (80) | 75 (57.3) | 0.040 |
| Ampicillin ( | 266 (91.1) | 31 (93.9) | 29 (100) | 14 (93.3) | 8 (100) | 12 (100) | 14 (100) | 9 (100) | 9 (100) | 9 (75) | 7 (100) | 10 (100) | 114 (85.1) | 0.124 |
| Ampicillin/sulbactam ( | 141 (64.4) | 15 (65.2) | 16 (69.6) | 5 (50) | 2 (40) | 12 (100) | 10 (100) | 3 (60) | 3 (42.9) | 5 (45.5) | 3 (75) | 2 (20) | 65 (65.7) | 0.001 |
| Piperacillin ( | 184 (85.6) | 18 (90) | 23 (95.8) | 8 (72.7) | 4 (66.7) | 12 (100) | 11 (100) | 6 (85.7) | 5 (100) | 7 (63.6) | 5 (100) | 9 (90) | 76 (81.7) | 0.125 |
| Piperacillin/tazobactam ( | 57 (14.5) | 2 (4.7) | 9 (22.5) | 3 (13.6) | 6 (35.3) | 2 (12.5) | 1 (6.7) | 1 (10) | 2 (18.2) | 0 | 0 | 0 | 31 (16.6) | 0.084 |
| Aztreonam ( | 130 (44.1) | 12 (33.3) | 19 (67.9) | 4 (22.2) | 2 (25) | 11 (84.6) | 9 (60) | 1 (12.5) | 5 (62.5) | 6 (54.5) | 4 (44.4) | 4 (40) | 53 (40.5) | 0.001 |
| Cefatriaxone ( | 253 (63.2) | 18 (46.2) | 34 (85) | 8 (34.8) | 12 (66.7) | 16 (94.1) | 12 (92.3) | 9 (75) | 7 (58.3) | 6 (50) | 5 (55.6) | 10 (100) | 116 (59.5) | <0.001 |
| Cefazolin ( | 210 (82.7) | 16 (66.7) | 27 (93.1) | 11 (78.6) | 6 (75) | 12 (100) | 11 (100) | 7 (100) | 6 (100) | 7 (58.3) | 5 (100) | 10 (100) | 92 (79.3) | 0.019 |
| Cefepime ( | 209 (50.9) | 16 (37.2) | 26 (65) | 5 (21.7) | 9 (50) | 14 (82.4) | 11 (68.8) | 6 (46.2) | 7 (58.3) | 5 (41.7) | 7 (63.6) | 7 (70) | 96 (49) | 0.006 |
| Cefoperazone/sulbactam ( | 57 (16) | 2 (4.8) | 3 (8.8) | 2 (9.5) | 1 (9.1) | 3 (23.1) | 3 (20) | 2 (20) | 4 (36.4) | 2 (16.7) | 2 (22.2) | 0 | 33 (19.5) | 0.158 |
| Cefotaxime ( | 198 (62.5) | 15 (41.7) | 25 (80.6) | 5 (27.8) | 6 (50) | 12 (92.3) | 12 (100) | 8 (72.7) | 4 (57.1) | 6 (50) | 4 (57.1) | 10 (100) | 91 (61.5) | <0.001 |
| Cefoxitin ( | 73 (20.7) | 5 (16.7) | 4 (11.1) | 2 (9.1) | 4 (26.7) | 6 (42.9) | 5 (38.5) | 2 (18.2) | 1 (9.1) | 0 | 4 (50) | 0 | 40 (23.3) | 0.024 |
| Ceftazidime ( | 167 (40.8) | 15 (34.9) | 26 (65) | 5 (21.7) | 9 (50) | 10 (58.8) | 8 (50) | 3 (23.1) | 3 (27.3) | 3 (25) | 5 (45.5) | 2 (20) | 78 (40) | 0.018 |
| Cefuroxime ( | 242 (67.6) | 17 (53.1) | 32 (84.2) | 9 (39.1) | 12 (70.6) | 16 (100) | 11 (91.7) | 7 (100) | 6 (54.5) | 6 (50) | 6 (75) | 10 (100) | 110 (64) | <0.001 |
| Ertapenem ( | 3 (2.5) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ND | 3 (5.0) | 1.000 |
| Imipenem ( | 7 (2.3) | 2 (5.4) | 0 | 0 | 0 | 0 | 0 | 0 | 1 (14.3) | 0 | 0 | 0 | 4 (2.9) | 0.716 |
| Meropenem ( | 7 (2.3) | 2 (5.4) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (10) | 4 (2.8) | 0.781 |
| Trimethoprim/sulfamethoxazole ( | 285 (70.7) | 26 (60.5) | 27 (69.2) | 19 (82.6) | 14 (87.5) | 15 (100) | 12 (75.0) | 10 (76.9) | 9 (75) | 8 (66.7) | 7 (63.6) | 7 (70) | 131 (67.9) | 0.179 |
| Nitrofurantoin ( | 14 (10.1) | 3 (21.4) | 1 (7.1) | 0 | ND | 0 | 0 | 0 | 0 | 0 | 2 (100) | 0 | 8 (13.1) | 0.092 |
| Ciprofloxacin ( | 268 (71.7) | 40 (100) | 39 (97.5) | 7 (41.2) | 12 (75) | 17 (100) | 6 (40) | 3 (27.3) | 9 (81.8) | 7 (63.6) | 10 (100) | 0 | 118 (67) | <0.001 |
| Levofloxacin ( | 275 (67.1) | 43 (100) | 39 (97.5) | 7 (30.4) | 13 (72.2) | 16 (94.1) | 5 (31.3) | 3 (23.1) | 10 (83.3) | 7 (58.3) | 11 (100) | 1 (10) | 120 (61.5) | <0.001 |
| Minocycline ( | 76 (35.8) | 7 (22.6) | 4 (19) | 4 (44.4) | 0 | 8 (80) | 4 (36.4) | 1 (14.3) | 0 | 2 (22.2) | 1 (16.7) | 9 (90) | 36 (40) | <0.001 |
| Tetracycline ( | 161 (80.5) | 17 (73.9) | 19 (82.6) | 7 (77.8) | 4 (80) | 11 (100) | 10 (90.9) | 0 | 5 (83.3) | 8 (72.7) | 2 (50) | 10 (100) | 68 (81.9) | 0.013 |
| ESBL phenotype ( | 184 (58.8) | 11 (44) | 23 (71.9) | 7 (31.8) | 10 (83.3) | 13 (86.7) | 7 (63.6) | 7 (77.8) | 6 (66.7) | 6 (60) | 3 (42.9) | 10 (100) | 81 (53.6) | 0.001 |
| MDR | 272 (66.2) | 27 (62.8) | 36 (90) | 12 (52.2) | 13 (72.2) | 17 (100) | 12 (75) | 4 (30.8) | 11 (91.7) | 8 (66.7) | 7 (63.6) | 8 (80) | 117 (59.7) | <0.001 |
| Resistance scoree, median (IQR) | 8 (3.5-13) | 7 (3–13) | 10.3 (7.1–14.9) | 6 (2.5–8.5) | 8 (2.8–10.6) | 13 (8.5–16.3) | 12.3 (5.1–14.4) | 7.5 (2.8–8.8) | 7.3 (5.3–13.4) | 7.8 (5.6–12.8) | 6.5 (3.5–14) | 10.5 (8.9–12) | 7.8 (2.6–12.9) | 0.001 |
FIGURE 1The number of larvae killed in a G. mellonella infection model according to CH or ST types among the 74 ExPEC isolates. Lethality in larvae (10 larvae/E. coli strain) was observed for 4 days after infection with test strains. Each dot corresponds to one test strain, its corresponding abscissa represents the average number of three independent experiments for the strain, and its corresponding ordinate represents the CH or ST types of the strain. Non-infected larvae and PBS challenged larvae showed no mortality. Low larvae mortality (≤20%) was recorded following challenge with E. coli DH5α. The Mann–Whitney U test showed the number of larvae killed in CH14-64, CH40-30, and CH35-27 groups were not statistically different, but higher than that in any of the remaining groups (P < 0.05).
Associations between the number of larvae killed (experimental virulence) and the presence of a virulence factor (VF) among the 74 ExPEC strains.
| Adherence | ||||||
| Afimbrial adhesin AFA-I | 2 | (0–0)c | 72 | 4 (2–9) | 0.037 | |
| 3 | 0 (0–0)d | 71 | 4 (2–9) | 0.038 | ||
| 3 | 0 (0–0)d | 71 | 4 (2–9) | 0.038 | ||
| Dr. adhesins | 3 | 0 (0–0)d | 71 | 4 (2–9) | 0.038 | |
| F1845 fimbrial adhesin | 3 | 0 (0–0)d | 71 | 4 (2–9) | 0.038 | |
| P fimbriae | 48 | 7 (2.3–9) | 26 | 2 (0–3) | <0.001 | |
| 46 | 8.5 (3–9) | 28 | 2 (0–3) | <0.001 | ||
| 55 | 5 (2–9) | 19 | 2 (1–3) | 0.015 | ||
| Type 1 fimbriae | 52 | 7 (3–9) | 22 | 1.5 (0–2.3) | <0.001 | |
| Autotransporter | ||||||
| Sat | 34 | 9 (4–9.3) | 40 | 2 (1–4) | <0.001 | |
| Invasion | ||||||
| AslA | 67 | 4 (2–9) | 7 | 0 (0–3) | 0.015 | |
| K1 capsule | 51 | 5 (2–9) | 23 | 2 (1–4) | 0.019 | |
| Iron uptake | ||||||
| Aerobactin | 48 | 5 (2–9) | 26 | 2 (1–4.3) | 0.024 | |
| 48 | 5 (2–9) | 26 | 2 (1–4.3) | 0.024 | ||
| 48 | 5 (2–9) | 26 | 2 (1–4.3) | 0.024 | ||
| 50 | 5.5 (2–9) | 24 | 2 (1–3.8) | 0.002 | ||
| Chu | 50 | 8.5 (2.8–9.3) | 24 | 1.5 (0–3) | < 0.001 | |
| 55 | 5 (2–9) | 19 | 2 (0–3) | <0.001 | ||
| 44 | 5 (2.3–9) | 30 | 2 (0–4.3) | 0.004 | ||
| 56 | 5 (2–9) | 18 | 1 (0–2.3) | <0.001 | ||
| 57 | 5 (2–9) | 17 | 1 (0–2.5) | <0.001 | ||
| 57 | 5 (2–9) | 17 | 1 (0–2.5) | < 0.001 | ||
| 45 | 5 (2–9) | 29 | 2 (0–5.5) | 0.019 | ||
| 56 | 5 (2–9) | 18 | 1 (0–2.3) | <0.001 | ||
| Shu | 37 | 6 (2–9.5) | 37 | 2 (0–5) | 0.003 | |
| Enterobactin | 49 | 2 (0.5–4) | 25 | 9 (8.5–10) | <0.001 | |
| Yersiniabactin | 59 | 5 (2–9) | 15 | 2 (0–3) | 0.008 | |
| 59 | 5 (2–9) | 15 | 2 (0–3) | 0.008 | ||
| 58 | 5 (2–9) | 16 | 1.5 (0–3) | 0.008 | ||
| 59 | 5 (2–9) | 15 | 2 (0–3) | 0.008 | ||
| 59 | 5 (2–9) | 15 | 2 (0–3) | 0.008 | ||
| 59 | 5 (2–9) | 15 | 2 (0–3) | 0.008 | ||
| 59 | 5 (2–9) | 15 | 2 (0–3) | 0.008 | ||
| 59 | 5 (2–9) | 15 | 2 (0–3) | 0.008 | ||
| 59 | 5 (2–9) | 15 | 2 (0–3) | 0.008 | ||
| 59 | 5 (2–9) | 15 | 2 (0–3) | 0.008 | ||
| 59 | 5 (2–9) | 15 | 2 (0–3) | 0.008 | ||
| Secretion system | ||||||
| T3SS | 41 | 2 (0–4) | 33 | 9 (4–9) | <0.001 | |
| 28 | 2 (1–4.8) | 46 | 5 (2–9) | 0.015 | ||
| 38 | 2 (0–4) | 36 | 9 (3–9) | 0.001 | ||
| 41 | 2 (0–4) | 33 | 9 (4–9) | <0.001 | ||
| 36 | 2 (0–4) | 38 | 8.5 (3–9) | 0.001 | ||
| 32 | 2 (1–4.8) | 42 | 5 (2.8–9) | 0.014 | ||
| 16 | 2 (1–3.8) | 58 | 5 (2–9) | 0.007 | ||
| T2SS | 55 | 3 (1–9) | 19 | 9 (2–10) | 0.044 | |
| 55 | 3 (1–9) | 19 | 9 (2–10) | 0.044 | ||
| 55 | 3 (1–9) | 19 | 9 (2–10) | 0.044 | ||
| 55 | 3 (1–9) | 19 | 9 (2–10) | 0.044 | ||
| 55 | 3 (1–9) | 19 | 9 (2–10) | 0.044 | ||
| 55 | 3 (1–9) | 19 | 9 (2–10) | 0.044 | ||
| 56 | 3 (1–8.8) | 18 | 9 (2.8–10) | 0.014 | ||
| 64 | 3 (1–9) | 10 | 9.5 (4.3–10) | 0.021 | ||
| 63 | 3 (1–9) | 11 | 9 (5–10) | 0.012 | ||
| Toxin | ||||||
| ShET2 | 28 | 9 (4–10) | 46 | 2 (1–5) | 0.001 | |
FIGURE 2ARG (A) and VF (B) scores according to CH or ST types among the 74 ExPEC isolates. ARG and VF scores were defined as the number of unique ARG and VF detected for each isolate, respectively. ARG scores in CH37-27 isolates were significantly higher than in CH14-64 or CH13-5 isolates while ARG scores in CH26-5 isolates were significantly higher than in CH40-30 or CH13-5 isolates (P < 0.05). VF scores in CH13-5 isolates were significantly higher than in any of these 12 groups (except CH26-65) while VF scores in CH11-54 isolates were significantly lower than in any of these 12 groups (except ST648 and Others) (P < 0.05).